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Background: In Poland, the prevalence of cardiovascular diseases is increasing. This might be associated with the
constantly growing proportion of elderly people and inappropriate cardiovascular prevention. This study aimed to
evaluate the frequency of use of oral antiplatelet (OAP) and oral anticoagulant (OAC) drugs among older people in
Poland and to assess their association with cardiovascular risk factors.
Methods: The study was based on data collected during the implementation of a multicentre, publicly funded
research project called PolSenior.
Results: The study group consisted of 4,979 people with the average age of 79.35 ± 8.69 years. Among them, 1,787
people (35.9%) used at least one drug in the prevention of cardiovascular diseases. OAPs were used regularly by
1,648 (33.1%) elderly people and OACs were used by 165 elderly people (3.3%). Acetylsalicylic acid was used by
32.2% of elderly people. Use of drugs significantly depended on age (p < 0.01), sex (p < 0.01), place of residence
(p < 0.001), level of education (p < 0.0001) and personal income (p < 0.0001). Among all the respondents treated
with OAPs, therapy was applied as secondary cardiovascular prevention in 717 respondents (43.5%), and as primary
prevention in 705 respondents (42.8%). Among the respondents treated with OACs, 117 (71%) elderly people had a
history of atrial fibrillation. Secondary cardiovascular prevention should be considered in a further 482 respondents
(15.1% of untreated elderly people), and primary cardiovascular prevention in 1,447 respondents (45.3%).
Conclusions: Our study is the first to determine the frequency of use of OAP and OAC drugs among elderly
people in Poland in relation to cardiovascular risk factors. The most commonly used drug for cardiovascular
prevention is acetylsalicylic acid, but it appears that it is used too rarely in high-risk patients. Educational programs
should be developed among general practitioners concerning current recommendations for pharmacological
cardiovascular prevention.
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Acetylsalicylic acidBackground
Cardiovascular disease is the most common cause of
mortality in elderly people worldwide, reaching 17 mil-
lion annually [1]. The incidence of stroke, as well as
myocardial infarction, increases dramatically with age,
and age is the strongest risk factor for cardiovascular
diseases. Although in Western European countries the* Correspondence: beatamaria.pl@hoga.pl
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distribution, and reproduction in any mediumincidence of coronary heart disease and stroke has been
decreasing since the 1970s, in Poland and other Eastern
European countries the prevalence of cardiovascular dis-
ease is still increasing [2,3]. This might be associated
with the constantly growing proportion of elderly people
and inappropriate cardiovascular prevention.
The most popular drugs used worldwide in prevention
of cardiovascular incidents are antiplatelet agents. One
of these agents is acetylsalicylic acid (ASA), registered in
1897 by Felix Hoffman as aspirin [4]. Initially, ASA was
used as an anti-inflammatory, antipyretic and analgesicentral Ltd. This is an Open Access article distributed under the terms of the
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ered in the 1960s, and since then, the drug has been
widely used in primary or secondary prevention of car-
diovascular diseases [6,7]. The occurrence of myocardial
infarction and stroke has been reduced by 25% in
patients regularly taking ASA [8]. Other oral antiplatelet
(OAP) drugs are recommended to people with contrain-
dications to ASA (e.g., ticlopidine, clopidogrel, and di-
pyridamole) [9].
Another group of medications used in prevention of
cardiovascular incidents are oral anticoagulant (OAC)
drugs, such as acenocoumarol and warfarin. These
agents block the receptors responsible for the binding of
vitamin K necessary for the normal blood clotting
process [10]. These drugs are especially recommended
for stroke prevention in people with atrial fibrillation,
with the presence of thrombus in the left ventricle, after
anterior myocardial infarction, and in some other spe-
cific clinical situations [10].
No studies have assessed the frequency of use of car-
diovascular preventive therapy in elderly people in Pol-
and or in other Eastern European countries. Therefore,
this study aimed to evaluate the frequency of use of
OAP and OAC drugs among older people in Poland and
to assess its association with cardiovascular risk factors.
Methods
Description of the project
This study was based on data collected during the im-
plementation of a multicentre, publicly funded research
project commissioned by the Polish Ministry of Science
and Higher Education called “Medical, psychological,
sociological and economic aspects of aging of people in
Poland (PolSenior)” (PBZ-MEiN-9/2/2006). The project
was carried out during 3 years (from October 2008 to
October 2010). The total number of participants was
5,695 (2,899 males and 2,796 females), including 4,979
people aged 65 and older, and 716 people at the thresh-
old of old age (55-59 years). Research participants were
randomly recruited in bundles, in a stratified, propor-
tional draw performed in three stages, as described pre-
viously [11]. Each participant was asked to complete a
questionnaire consisting of two parts: medical and socio-
economic. The medical part of the questionnaire
included detailed questions about their present health
status, as well as history of diseases, hospitalisations, and
current medications. The socioeconomic part of the
questionnaire included questions concerning the per-
sonal and family situation, economic status, household
structure, leisure activities, hobbies, and social life,
among others. English versions of the medical and socio-
economic questionnaires are available on-line (http://
polsenior.iimcb.gov.pl/en/questionnaire). The medical
part of the questionnaire was completed during the firstvisit, while the socioeconomic part was completed dur-
ing the second visit. When the participant was unable to
answer the questions, a caregiver was asked. During the
third visit, blood and urine samples were taken and
delivered within 2 h to local laboratories. In all the parti-
cipants, body weight and height were also measured,
and the body mass index (BMI) was calculated. Arterial
blood pressure and pulse were measured three times
(during each visit) by automatic blood pressure monitors
(A&D UA-787 Plus, validated by the British Hyperten-
sion Society). Each measurement was performed with
the participant in a seated position, on the right upper
arm, after at least 5 min of rest and at 2-min intervals.
The PolSenior project was approved by the Bioethics
Commission of the Medical University of Silesia in Kato-
wice. Before enrolment in the study, each respondent or
their caregiver signed an informed consent form. A
detailed description of the project has been previously
described [11].
Study group
The study group included respondents from the PolSe-
nior project aged 65 years and older.
Data analysis
The frequency of use of drugs was based on the data
collected in the medical part of the questionnaire, in-
cluding the international and trade names of drugs taken
by participants.
The following data from the general PolSenior data-
base were also used and analysed: age, sex, place of resi-
dence (village or city, or staying at a nursing home),
education, professional status, personal income, and a
history of cardiovascular risk factors (coronary heart dis-
ease, previous myocardial infarction, congestive heart
failure, pharmacologically treated hypertension, a history
of atrial fibrillation, previous strokes, pharmacologically
treated diabetes, pharmacologically treated dyslipidemia,
and active smoking). Measurements of BMI, mean sys-
tolic blood pressure, and blood tests (total cholesterol)
were also analysed.
Statistical data analysis was performed using SAS ver-
sion 9.2 (SAS Institute Inc., Gary, NC). The level of stat-
istical significance was p ≤ 0.05. Diversity variables were
assessed based on the chi-square test or Fischer’s exact
test. We used the Kolmogorov-Smirnov test (N > 2000)
or Shapiro-Wilk test to check the compatibility of the
distribution of quantitative variables with normal distri-
bution. In the case of normal distribution, statistical sig-
nificance of differences between quantitative variables
was analysed using the Student’s t-test. When the distri-
bution diverged from normal, the nonparametric Wil-
coxon rank sum test was used. A model of logistic
regression was used to analyse the association between
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or OAC drugs.
The 10-year risk of fatal cardiovascular disease (Sys-
tematic Coronary Risk Evaluation [SCORE]) was calcu-
lated by using the following data: sex (male/female), age
(years), systolic blood pressure (mmHg), total cholesterol
(mmol/l) and history of current smoking [12].
The CHADS2 score for estimating the risk of stroke in
patients with atrial fibrillation was calculated by adding
together points for congestive heart failure (1 point),
hypertension (1 point), age ≥75 years (1 point), diabetes
mellitus (1 point), and previous stroke (2 points) [13].
Results
The study group consisted of 4,979 people aged from 65
to 104 years, including 2,567 men (51.56%) aged from 65
to 104 years and 2,412 women (48.44%) aged from 65 to
104 years. The mean age of the study group was 79.35 ±
8.69 years, the mean age of men was 79.48 ± 8.54 years,
and the mean age of women was 79.22 ± 8.86 years. The
age difference between men and women was not statisti-
cally significant (p = 0.21).
Among all the respondents, 1,787 people (35.9%) used
at least one drug in the prevention of cardiovascular dis-
eases. OAPs were regularly used by 1,648 respondents
(33.1%); 1,556 of them (31.3%) were taking one drug, 90
subjects (1.8%) were taking two drugs, and two of them
(0.04%) were taking three drugs. OACs were regularly
used by 165 people (3.3%). Antiplatelet and anticoagu-
lant therapy was simultaneously applied by 26 respon-
dents (0.5%) (Table 1).
With regard to other drugs applied in the treatment of
cardiovascular diseases, beta-blockers were used by
1,386 (27.8%) respondents, ACE inhibitors were used by
1,973 (39.6%) respondents, angiotensin II receptor
blockers were used by 343 (6.9%) respondents, calcium
channel blockers were used by 141 (2.8%) respondents,
and statins were used by 1,158 (23.3%) respondents.
The percentage of women using OAP and/or OAC
drugs (34.3%, n = 828) was significantly lower than the
corresponding percentage in men (37.4%, n = 959) (p <







OAP acetylsalicylic acid 1,604 (32.2%)
clopidogrel 57 (1.14%)
ticlopidine 81 (1.6%)
OAC acenocoumarol 158 (3.2%)
warfarin 18 (0.4%)
OAP - Oral antiplatelet drugs, OAC - Oral anticoagulant drugs.was statistically significantly dependent on age in women
(p < 0.01), men (p < 0.01), and all subjects (p < 0.01).
Drugs were most frequently taken in the age group of
80-84 years, and were most rarely taken in the youngest
age group (65-69 years).
Inhabitants of cities used OAP and/or OAC drugs sig-
nificantly more frequently (37.8%, n = 1130) than rural
residents (33.1%, n = 656) (p < 0.001).
We observed significant differences in the frequency
of OAPs and/or OACs use, depending on the prov-
ince where the respondents lived (p ≤ 0.05). Preventive
cardiovascular therapy was mostly applied by people
from Swietokrzyskie (46.6% of respondents living in
this region), Kujawsko-Pomorskie (40.7%), and Wielko-
polskie (40.1%), while the lowest amount was applied
by people living in Zachodniopomorskie (30.1%),
Podlaskie (30.2%), Podkarpackie (31.97%), and Lubus-
kie (31.97%).
The frequency of use of OAP and/or OAC drugs was
associated with the level of education (p < 0.0001).
People who were better educated used these drugs more
often. A total of 39.4% of respondents who had gradu-
ated from university applied the examined drugs, while
only 20.2% of people who declared a lack of education.
Personal income had a significant effect on the fre-
quency of use of OAP and/or OAC drugs (p < 0.0001).
Only 22.4% of people with the lowest income (up to 500
Polish zloty per month) used these drugs compared with
44.7% of those with the highest incomes (2501 or more
Polish zloty per month).
Professional activity of the study group did not affect
the frequency of prevention of cardiovascular disease.
The vast majority of responders were pensioners (87.9%,
n = 4222), and among them, 36.5% had used OAP and/
or OAC drugs. Eleven individuals declared unemploy-
ment (0.2%), and only one of them (9.1%) applied
pharmacological prevention of cardiovascular diseases. A
total of 108 respondents (2.3%) were housewives and
28.7% of them used OAP and/or OAC drugs. Active
professional people constituted less than 1% of all
respondents (0.9%, n = 44) and 38.6% of them used one
of the examined drugs.
There were 50 residents of nursing houses (1.1%) and
21 of them (42%) had used OAP and/or OAC drugs.
The frequency of cardiovascular risk factors in the
whole study group is shown in Table 2. The association
between use of OAP and/or OAC drugs and cardiovas-
cular risk factors is shown in Table 3.
Among all of the cardiovascular risk factors, hyperten-
sion was most associated with OAP treatment, a history
of atrial fibrillation was most associated with OAC treat-
ment, and coronary heart disease and male sex were
most associated with combined OAP and OAC therapy
(Table 4).
Table 2 Frequency of cardiovascular risk factors in the
whole study group (N = 4979)
Risk factor n (%) ND (n)
Pharmacologically treated hypertension 2941 -
(59.1%)
Previus myocardial infarct 554 156
(11.5%) (3.1%)
Previous stroke 426 27
(8.6%) (0.5%)






Congestive heart failure 531 184
(11.1%) (3.7%)
Pharmacologically treated diabetes 1006 982
(25.2%) (19.7%)
Pharmacologically treated dyslipidaemia 1258 -
(25.3%)
Current smoker 449 21
(9.1%) (0.4%)
Overweight/obesity 3337 355
(BMI≥ 25 kg/m2) (72.2%) (7.1%)
ND – not documented.
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indications for antiplatelet therapy. Among all of the
patients treated with OAPs (n = 1648), this therapy was
applied as secondary cardiovascular prevention (people
with previous myocardial infarction, previous stroke, and
history of coronary heart disease) in 717 respondents
(43.5%). On the other hand, 705 people (42.8%) used
OAP drugs in the primary prevention of cardiovascular
disease. Among them, 58 respondents (3.5%) had no
indications (SCORE <5%), 174 respondents (10.6%) had
relative indications (SCORE ≥5% and <10%), and 473
respondents (28.7%) had definitive indications (SCORE
≥10% and/or atrial fibrillation). It was impossible to es-
tablish indications in 226 respondents (13.7%) (lack of
data).
Among all the respondents treated with OACs (n =
165), 117 (71%) persons had a history of atrial fibrilla-
tion. Other indications for anticoagulant therapy could
not be established in this group because of the lack of
necessary data.
We also performed an analysis of optional indications
for preventive therapy among respondents not treated
with OAP or OAC drugs (n = 3192). Only 109 people
(3.4%) had no indications for such therapy (SCORE <5),
and 559 respondents (17.5%) had relative indications
(SCORE ≥5 and <10). Secondary cardiovascularpharmacological prevention should be considered in 482
respondents (15.1%), and primary cardiovascular
pharmacological prevention (SCORE ≥10 and/or atrial
fibrillation) should be considered in 1447 respondents
(45.3%). It was impossible to establish optional indica-
tions in 595 respondents (18.7%) (lack of data).
Among the patients with atrial fibrillation (n = 875),
the CHADS2 score was calculated in 679 people (lack of
data in 196 cases). Among the respondents with 0 points
(n = 33), seven persons (21.2%) were treated (all of them
with OAPs). Among the respondents with 1 point (n =
138), 47 persons (34.1%) used OAPs and 14 persons
(10.1%) used OACs. Among the respondents with 2 or
more points (n = 508), 254 persons (50%) received OAPs
and 76 persons (15%) received OACs.Discussion
The percentage of elderly people in Poland (65 years and
older) is currently 13.4%, and it has still been growing by
approximately 2% over the last decade [14]. The PolSe-
nior project was the first study in Poland involving such
a large group of older people and concerning various
aspects of their lives (health, social and economic). The
study involved nearly 5,000 people aged 65 years and
older, which constitutes approximately 1% of all Polish
citizens in that age category.
Until the current study, there were no studies con-
cerning the frequency of use of antiplatelet and anti-
coagulant drugs in the prevention of cardiovascular
diseases in elderly people in Poland. Similar research in
other countries is rare [15-18]. Our study showed that,
in Poland, ASA is the most commonly used drug in pre-
vention of thromboembolic events in elderly people.
This medicine was regularly taken by as many as 32% of
PolSenior respondents, both for primary and secondary
prevention of cardiovascular disease. ASA use among
adults aged 40 years and older in the United States is
41% (data from a nationally representative Internet-
based survey involving 1299 adults) [18]. Other antipla-
telet drugs were used less frequently in Poland, with
ticlopidine used slightly more than clopidogrel (1.6% vs
1.14%), which might be attributed to the price of the
drug. Until recently, the preparations of ticlopidine in
Poland were much cheaper than the preparations of clo-
pidogrel. It should be noted that despite similar mechan-
isms of action, these drugs significantly differ from each
other. Ticlopidine is characterised by a slower time of
action, making the drug useless in acute coronary syn-
dromes, and is less convenient, with dosing twice a day.
Clopidogrel acts much faster than ticlopidine, has less
frequent side effects (e.g., gastrointestinal bleeding), and
its once-daily dosing is better for the patient. Dual anti-
platelet therapy was used by 90 respondents (1.81%). In
Table 3 Frequency of use of OAP and/or OAC in association with the cardiovascular risk factors
Risk factor OAP or OAC OAP OAC OAP and OAC
n (%) n (%) n (%) n (%)
Pharmacologically treated hypertension 1480 1354 151 25
(50.32%) (46.04%) (5.13%) (0.85%)
Previus myocardial infarct 375 350 35 10
(67.69%) (63.18%) (6.32%) (1.81%)
Previous stroke 261 237 25 1
(61.27%) (55.63%) (5.87%) (0.23%)
History of atrial fibrilation 498 396 117 15
(56.91%) (45.26%) (13.37%) (1.71%)
Coronary heart disease (without myocardial infarct) 426 382 58 14
(61.21%) (54.89%) (8.33%) (2.01%)
Congestive heart failure 341 290 61 10
(64.22%) (54.61%) (11.49%) (1.88%)
Pharmacologically treated diabetes 471 432 43 4
(46.82%) (42.94%) (4.27%) (0.40%)
Pharmacologically treated dyslipidaemia 795 726 86 17
(63.20%) (57.71%) (6.84%) (1.35%)
Current smoker 132 123 10 1
(29.40%) (27.39%) (2.23%) (0.22%)
Overweight/obesity 1278 1159 142 23
(BMI≥ 25 kg/m2) (38.30%) (34.73%) (4.26%) (0.69%)
Data presented as n (%).
OAP - Oral antiplatelet drugs, OAC - Oral anticoagulant drugs.
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ticlopidine.
It is interesting that dipyridamole was not used in Pol-
and. This drug is recommended in combination with
ASA for secondary prevention of cardiovascular disease
in patients after stroke [19]. Some large randomised clin-
ical trials have confirmed the effectiveness of such action
[20]. However, pharmacoeconomics represents an obs-
tacle for common use of such combination of drugs.
According to data from the United States, the monthly
cost of treatment with dipyridamole and ASA is much
higher (~$122) than the monthly cost of treatment with
ASA alone (less than $2) [21]. In Poland, the price, as
well as the low availability of dipyridamole, pose a
problem.
New antiplatelet drugs, such as ticagrelor, which re-
versibly binds the P2Y12 receptor and noncompetitively
blocks adenosine diphosphate-induced platelet activa-
tion, were not commonly used in Poland when the study
was performed. Therefore, no participant in our study
had used them.
The most widely used OAC in Poland is acenocou-
marol (more than 3% of respondents), which is in con-
trast to the United States and Western Europe, where
warfarin is more popular. Until recently, warfarin wasunavailable in Poland. Now it is prescribed more often.
Warfarin was only used by 18 respondents (0.4%). New
anticoagulants, such as dabigatran and rivaroxaban, were
not used by the examined people.
The decision to begin therapy with an antiplatelet drug
should be undertaken after assessing a global cardiovas-
cular risk. Following the current European guidelines,
ASA is recommended in all patients with an established
cardiovascular disease (coronary heart disease, previous
strokes, and previous myocardial infarctions) unless
there are any contraindications [22]. In asymptomatic
people, ASA should be considered when the risk of
death from a cardiovascular disease is high (5% or
greater in the next 10 years) [22]. SCORE tables are used
to estimate this 10-year-long risk of death [12,22]. On
the basis of the underlying risk factors, such as sex, age,
systolic blood pressure, total cholesterol, and a history of
smoking, the risk of death from cardiovascular causes in
patients aged 40 and older can be determined. However,
this scale is less suitable for older people because the
estimated risk almost always exceeds 5% because of age
(and sex), while other risk factors remain low [22]. This
explains why, for the purposes of this study, we identi-
fied a group of people with a SCORE result between 5%
and 9%, and considered that they had relative indications
Table 4 Association of cardiovascular risk factors with OAP and/or OAC treatment
Risk factor OAP or OAC OAP OAC OAP and OAC
Pharmacologically treated hypertension 3.62 3.48 3.12 3.87
(3 - 4.37) (2.88 - 4.21) (1.56 - 6.23) (0.46 - 32.58)
p < 0.01 p < 0.01 p < 0.01 NS
Previus myocardial infarct 2.53 2.67 0.71 2.19
(1.93 - 3.31) (2.06 - 3.45) (0.43 - 1.19) (0.8 - 5.95)
p < 0.01 p < 0.01 NS NS
Previous stroke 2.84 2.19 2.31 0.38
(2.11 - 3.83) (1.65 - 2.91) (1.35 - 3.96) (0.05 - 3.05)
p < 0.01 p < 0.01 p < 0.01 NS
History of atrial fibrilation 1.54 0.95 9.01 1.64
(1.25 - 1.89) (0.77 - 1.16) (5.74 - 14.14) (0.59 - 4.57)
p < 0.01 NS p < 0.01 NS
Coronary heart disease (without myocardial infarct) 1.66 1.65 1.2 4.15
(1.32 - 2.08) (1.32 - 2.05) (0.77 - 1.86) (1.47 - 11.71
p < 0.01 p < 0.01 NS p = 0.01
Congestive heart failure 1.67 1.36 1.87 1.97
(1.28 - 2.17) (1.06 - 1.76) (1.2 - 2.92) (0.69 - 5.63)
p < 0.01 p = 0.02 p = 0.01 NS
Pharmacologically treated diabetes 1.22 1.23 0.91 0.34
(1.02 - 1.47) (1.03 - 1.47) (0.6 - 1.4) (0.09 - 1.22)
p = 0.03 p = 0.02 NS NS
Pharmacologically treated dyslipidaemia 2.77 2.5 1.84 3.61
(2.32 - 3.31) (2.11 - 2.98) (1.22 - 2.76) (1.2 - 10.88)
p < 0.01 p < 0.01 p < 0.01 p = 0.02
Current smoker 0.78 0.8 0.72 0.39
(0.58 - 1.06) (0.6 - 1.09) (0.32 - 1.62) (0.05 - 3.28)
NS NS NS NS
Previus smoker 0.92 0.97 0.61 0.32
(0.76 - 1.11) (0.8 - 1.17) (0.38 - 0.97) (0.11 - 0.94)
NS NS p = 0.04 p = 0.04
Overweight/obesity 0.91 0.82 2.44 1.44
(0.75 - 1.09) (0.68 - 0.98) (1.33 - 4.5) (0.39 - 5.31)
(BMI≥ 25 kg/m2) NS p = 0.03 p < 0.01 NS
Sex (male) 1.44 1.33 2.07 4.14
(1.2 - 1.73) (1.11 - 1.6) (1.32 - 3.25) (1.34 - 12.78)
p < 0.01 p < 0.01 p < 0.01 p = 0.01
Data are presented as OR (95%CI) and p-value.
OAP - Oral antiplatelet drugs, OAC - Oral anticoagulant drugs.
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lieve that a SCORE result of 10% or higher better indi-
cates the necessity for cardiovascular pharmacological
prevention in older people [23].
We found that in Poland, antiplatelet drugs should be
used more often. For example, 482 untreated respon-
dents (15.1%) had a recognised cardiovascular diseaseand 1230 untreated asymptomatic respondents (38.5%)
had an estimated SCORE ≥10%. After stroke, approxi-
mately 60% of people took medications, which is less
than that in Western Europe [15], but is similar to the
inhabitants of Asian countries [16]. Those with a history
of myocardial infarction applied secondary prevention
slightly more often than people after stroke (~70%).
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one risk factor (age ≥ 65 years); therefore, according to
current guidelines, anticoagulant therapy should be con-
sidered for all these patients [24]. Our results showed
that only 13% of the examined people with atrial fibrilla-
tion had used OACs, and slightly more than 40% used
OAPs. This percentage appears to be inadequate, but we
could not establish the reasons for omitting such a ther-
apy (lack of data). It also appears that OACs were insuf-
ficiently used in patients after a stroke with concomitant
atrial fibrillation (only one-fifth of patients). Analysis of
CHADS2 score which estimates the risk of stroke in
patients with atrial fibrillation confirms not adequate use
of OACs in people with atrial fibrillation.
An important and common risk factor for cardiovas-
cular disease is diabetes mellitus. Currently, recommen-
dations for the use of antiplatelet drugs in diabetes have
changed; they are similar to those for people without
diabetes. Recent randomised clinical trials and meta-
analyses have not confirmed the effectiveness of ASA in
primary prevention of cardiovascular disease in diabetic
patients. It has been shown that the use of ASA in
people with diabetes and a low risk of cardiovascular
disease (<5%) does not significantly affect the occurrence
of cardiovascular events, but significantly increases the
risk of bleeding complications (mainly haemorrhagic
stroke and gastrointestinal bleeding) [25-28]. Among our
respondents, 1399 people had diabetes, which consti-
tuted 28% of the whole study group. Less than 50% of
them used OAP and/or OAC drugs.
The side effects of OAP and OAC therapy (mainly
gastrointestinal and brain haemorrhage) should be con-
sidered. A benefit-to-risk ratio should be estimated in
every patient [29]. The lack of data did not allow us to
estimate such a ratio in the examined group of patients.
Limitations of the study
A lack of data in some cases was an obstacle to estimate
the indications for therapy in all of the respondents.
Hypertension was recognised only in people treated with
antihypertensive drugs, diabetes was recognised in
people treated with insulin or oral drugs, and dyslipidae-
mia was recognised in people treated with statins or
fibrates. Coronary heart disease and congestive heart
failure were recognised only when they were documen-
ted (hospitalisation). The reasons for abandonment of
therapy (contraindications) could not be established be-
cause of the lack of data.
The total responder rate in the study was rather low
(42.58%; described in a previous paper) [11]. We pre-
sume that people who decided to take part in the project
better adhered to medical recommendation and cared
about their health more than those who refused. There-
fore, the number of older people treated with OAP and/or OAC drugs in Poland could be even lower than ori-
ginally described.
Conclusions
Our study shows that the total percentage of treated eld-
erly people with an indication for antiplatelet and/or
anticoagulant therapy is too low in Poland. The most
popular drug used in the prevention of cardiovascular
diseases is ASA. The frequency of use of OAP and OAC
drugs in elderly people is significantly affected by age,
sex, place of residence, level of education, and personal
income. Among the thienopyridine derivatives, ticlopi-
dine is the most popular medication in Poland. OAC
drugs are applied too rarely among older people with
atrial fibrillation. Acenocoumarol is more popular than
warfarin. Dipyridamole, as well as new anticoagulant
drugs (e.g., dabigatran and rivaroxaban) and new antipla-
telet drugs (e.g., ticagrelor), are not used in elderly
people in Poland. It is necessary to develop educational
programs among general practitioners concerning
current recommendations for pharmacological cardio-
vascular prevention.
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